Skip to main content
诺思兰德 logo

诺思兰德 — Investor Relations & Filings

Ticker · 920047 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 539 across all filing types
Latest filing 2025-04-22 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920047

About 诺思兰德

https://www.northland-bio.com/

Northland Biotech focuses on the research, development, and commercialization of gene therapies and recombinant protein pharmaceuticals. The company’s primary therapeutic areas include cardiovascular diseases, peripheral arterial diseases, and ophthalmology. Its core R&D pipeline features NL003, a hepatocyte growth factor gene therapy targeting critical limb ischemia, and NL005, a recombinant human thymosin beta 4 for treating myocardial ischemia. Beyond its innovative pipeline, the company maintains advanced manufacturing facilities for biologics and ophthalmic preparations, producing a range of specialized eye drops. By leveraging its proprietary technology platforms, Northland Biotech aims to provide effective treatments for chronic and degenerative conditions through advanced molecular medicine.

Recent filings

Filing Released Lang Actions
2024年度独立董事述职报告(任自力)
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Report for 2024" from Beijing Northland Biotechnology Co., Ltd. It details the independent director's duties, attendance at meetings, supervision activities, communication with auditors, and evaluation of company governance and compliance during the year 2024. It includes no financial statements or quarterly/annual financial data but focuses on the director's role, oversight, and governance activities. This type of document is a report on board/management information, specifically about the independent director's duties and activities. It is not an annual report, audit report, or earnings release. Therefore, the appropriate classification is Board/Management Information (MANG). The document length (5622 characters) supports it being a full report rather than a brief announcement or certification.
2025-04-22 Chinese
2025年一季度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled "北京诺思兰德生物技术股份有限公司 2025 年第一季度报告" which translates to "Beijing Northland Biotechnology Co., Ltd. 2025 First Quarter Report." It contains detailed financial statements including consolidated balance sheets, profit and loss statements, cash flow statements, and notes on financial data for the period ending March 31, 2025. The document explicitly states it is a quarterly report and includes comprehensive financial data and analysis for the first quarter of 2025. It is unaudited but contains substantive financial information, which fits the definition of an Interim / Quarterly Report (IR). The document is lengthy (15,000 characters) and contains actual financial statements, not just an announcement or certification. Therefore, the correct classification is IR with high confidence. Q1 2025
2025-04-22 Chinese
2024年年度股东大会通知公告
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2024 Annual General Meeting (AGM) of Beijing Northland Biotechnology Co., Ltd. It includes information about the meeting date, voting methods (including online voting), agenda items to be discussed and approved at the AGM, such as the 2024 board work report, supervisory board report, independent directors' reports, audit firm appointment, special reports on fund usage, internal control evaluation, non-operating fund occupation, remuneration plans, financial reports, annual report, and dividend distribution plan. The document also provides registration details for shareholders attending the meeting and other procedural information. The document is not the annual report itself but a formal announcement and notice of the AGM, including the agenda and procedural details. It references other documents published on the stock exchange website but does not contain the full reports or financial statements. The document length is about 5,445 characters, which is consistent with a notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2025-04-22 Chinese
关于获得发明专利证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a US invention patent certificate. It details the patent name, patent number, application date, validity period, and the impact on the company. There is no financial data, no mention of financial results, no regulatory filings or certifications, and no reference to meetings or votes. The document is an official announcement about intellectual property rights, which does not fit into financial report categories like Annual Report, Interim Report, or Earnings Release. It is also not related to management changes, capital updates, or legal proceedings. The best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other categories.
2025-04-13 Chinese
关于全资子公司完成工商变更登记并取得换发营业执照的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of a business registration change and the issuance of a new business license for a wholly-owned subsidiary of the company. It details the increase in registered capital of the subsidiary and references previous announcements about the capital increase. The document is short (1146 characters) and serves as a formal public notice of a corporate event related to capital structure changes at the subsidiary level. It does not contain financial statements, audit information, or detailed management discussion. It is not a report or presentation but an official announcement of a capital change event. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2025-03-23 Chinese
关于控股股东、实际控制人及一致行动人续签《一致行动协议》的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the renewal of a "一致行动协议" (Agreement of Acting in Concert) between the controlling shareholders and actual controllers of the company. It details the background, main content, and impact of the renewed agreement on the company's control and decision-making. There is no financial data, no report attached or referenced as being published, and no mention of a meeting or voting results. The document focuses on shareholder agreements and control structure, which is a regulatory announcement about shareholding and control but does not fit the category of Major Shareholding Notification (MRQ) since it does not report a change in shareholding thresholds but rather the renewal of an agreement among existing controlling shareholders. It also does not fit into Board/Management Information (MANG) as it does not announce changes in board or management personnel. The best fitting category is Regulatory Filings (RNS), as it is a general regulatory announcement about shareholder agreements and control without fitting other specific categories.
2025-03-23 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.